Morgan Stanley’s ENDRA Life Sciences NDRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.5K | Sell |
3,546
-3,400
| -49% | -$13.5K | ﹤0.01% | 6796 |
|
|
2025
Q4 | $31.5K | Buy |
+6,946
| New | +$39.6K | ﹤0.01% | 6565 |
|
|
2025
Q1 | – | Sell |
-13
| Closed | -$81 | – | 8179 |
|
|
2024
Q4 | $81 | Sell |
13
-62
| -83% | -$413 | ﹤0.01% | 7500 |
|
|
2024
Q3 | $526 | Buy |
75
+69
| +1,150% | +$5.35K | ﹤0.01% | 7296 |
|
|
2024
Q2 | $1K | Buy |
+6
| New | +$2.58K | ﹤0.01% | 7154 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 7312 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 7173 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 7253 |
|
|
2023
Q2 | – | Sell |
-15
| Closed | -$42.2K | – | 7282 |
|
|
2023
Q1 | $58.9K | Sell |
15
-10
| -40% | -$67.9K | ﹤0.01% | 6217 |
|
|
2022
Q4 | $176K | Hold |
25
| – | – | ﹤0.01% | 5720 |
|
|
2022
Q3 | $265K | Buy |
25
+1
| +4% | +$10.3K | ﹤0.01% | 5587 |
|
|
2022
Q2 | $199K | Hold |
24
| – | – | ﹤0.01% | 5898 |
|
|
2022
Q1 | $332K | Hold |
24
| – | – | ﹤0.01% | 5626 |
|
|
2021
Q4 | $583K | Buy |
24
+17
| +243% | +$722K | ﹤0.01% | 5452 |
|
|
2021
Q3 | $402K | Hold |
7
| – | – | ﹤0.01% | 5628 |
|
|
2021
Q2 | $506K | Buy |
7
+1
| +17% | +$78.7K | ﹤0.01% | 5517 |
|
|
2021
Q1 | $573K | Buy |
+6
| New | +$449K | ﹤0.01% | 5077 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 6741 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 6246 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 6457 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6474 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6431 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 6482 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6313 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6401 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 6422 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 6447 |
|
Other funds holding NDRA
ACM
VFT
VCM
CIAM
Morgan Stanley's NDRA Position: Q1 2026 in Review
Morgan Stanley reduced its ENDRA Life Sciences (NDRA) stake by 49% in Q1 2026, selling an estimated $13.5K and leaving 3,546 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6796.
Morgan Stanley first reported a position in NDRA in Q1 2021 and has held it in 14 quarters since. The position peaked at $583K in Q4 2021. 8 funds tracked by Wall St. Rank hold NDRA as of Q1 2026.
- Morgan Stanley held 3,546 shares of ENDRA Life Sciences worth $16.5K as of Q1 2026.
- Morgan Stanley sold 3,400 ENDRA Life Sciences shares in Q1 2026, an estimated $13.5K.
- ENDRA Life Sciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6796 holding.
- Morgan Stanley first reported a position in ENDRA Life Sciences in Q1 2021 and has held it in 14 quarters since.
- Morgan Stanley's ENDRA Life Sciences position peaked at $583K in Q4 2021.
- 8 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.